ConductScience.org, home

Paper389478

Podophyllotoxin derivative VP 16-213.

Arnold AM. Cancer Chemother Pharmacol, 1979. Cited by 92 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Podophyllotoxin derivative VP 16-213. Papers, record 389478. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/389478

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Podophyllotoxin derivative VP 16-213.
PubMed
Journal
Cancer Chemother Pharmacol
PubMed
Year
1979
PubMed
Publication types
Clinical Trial, Journal Article, Review
PubMed
Citations, by iCite
92
iCite
Relative citation ratio, by iCite
4.91
iCite
Revised in PubMed
2019-08-27
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Arnold AMA M

Source PubMed

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
EtoposideMajor topic
NeoplasmsMajor topic
PodophyllotoxinMajor topic
Animals
Bronchial Neoplasms
Carcinoma
Clinical Trials as Topic
Drug Administration Schedule
Drug Evaluation
Drug Therapy, Combination
Humans
In Vitro Techniques
Leukemia, Monocytic, Acute
Leukemia, Myeloid
Lymphoma
Mice
Rabbits
Rats
Sarcoma

Source PubMed

References53

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
1679,171Structure-activity study of the inhibition of microtubule assembly in vitro by podophyllotoxin and its congeners.Cancer Res1978https://conductscience.org/library/papers/679171PubMed
2688,275Kinetics of cytotoxicity of VM-26 and VP-16-213 on L1210 leukemia and hematopoietic stem cells.Cancer Treat Rep1978https://conductscience.org/library/papers/688275PubMed
34,855,812Interaction of drugs with microtubule proteins.Fed Proc1974https://conductscience.org/library/papers/4855812PubMed
41,157,447PTG, a new antineoplastic epipodyphyllotoxin.Clin Pharmacol Ther1975https://conductscience.org/library/papers/1157447PubMed
54,634,038Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213).Cancer Chemother Rep1972https://conductscience.org/library/papers/4634038PubMed
64,578,134Epipodophyllotoxin VP 16213 in treatment of acute leukaemias, haematosarcomas, and solid tumours.Br Med J1973https://conductscience.org/library/papers/4578134PubMed
7657,164Evaluation of VP-16-213 in malignant lymphoma and melanoma.Cancer Treat Rep1978https://conductscience.org/library/papers/657164PubMed
81,016,966Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213.Cancer Treat Rep1976https://conductscience.org/library/papers/1016966PubMed
9939,236Combination chemotherapy with 4'Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-beta-D-glucopyranoside), VP 16-213 (NSC 141540) in L1210 leukemia.Eur J Cancer (1965)1976https://conductscience.org/library/papers/939236PubMed
10999,819Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells.Biochemistry1976https://conductscience.org/library/papers/999819PubMed
111,203,893Myocardial infarction in a 27-year-old woman: possible complication of treatemtn with VP-16-213 (NSC-141540), mediastinal irradiation, or both.Cancer Chemother Rep1975https://conductscience.org/library/papers/1203893PubMed
121,036,468Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer.Cancer Treat Rep1976https://conductscience.org/library/papers/1036468PubMed
131,009,527PHASE I clinical trial of an oral solution of VP-16-213.Cancer Treat Rep1976https://conductscience.org/library/papers/1009527PubMed
151,204,664Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotixin glucopyranoside derivatives.Eur J Cancer (1965)1975https://conductscience.org/library/papers/1204664PubMed
16348,319VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.Cancer Treat Rep1978https://conductscience.org/library/papers/348319PubMed
17657,168VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung.Cancer Treat Rep1978https://conductscience.org/library/papers/657168PubMed
18976,288Antimetastasis effect of two derivatives of epiposophyllotoxin in mice.Eur J Cancer (1965)1976https://conductscience.org/library/papers/976288PubMed
194,991,9324'-Demethyl-epipodophyllotoxin thenylidene glucoside (VM 26), a podophyllum compound with a new mechanism of action.Eur J Cancer (1965)1970https://conductscience.org/library/papers/4991932PubMed
20194,694Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma.Cancer Treat Rep1977https://conductscience.org/library/papers/194694PubMed
214,760,528Effects of a new antitumor agent, epipodophyllotoxin, on growth and chromosomes in human hematopoietic cell lines.Cancer Res1973https://conductscience.org/library/papers/4760528PubMed

See all 53 references

Cited by26

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 92 citations.

PMIDTitleJournalYearIn PapersSource
26,464,8226-Methoxy Podophyllotoxin Induces Apoptosis via Inhibition of TUBB3 and TOPIIA Gene Expressions in 5637 and K562 Cancer Cell Lines.Cell J2015https://conductscience.org/library/papers/26464822PubMed
23,849,350Preparation of hierarchical mesoporous CaCO3 by a facile binary solvent approach as anticancer drug carrier for etoposide.Nanoscale Res Lett2013https://conductscience.org/library/papers/23849350PubMed
15,139,794Pharmacokinetic optimisation of treatment with oral etoposide.Clin Pharmacokinet2004https://conductscience.org/library/papers/15139794PubMed
7,497,580Stability of the i.v. and oral formulations of etoposide in solution.Cancer Chemother Pharmacol1995https://conductscience.org/library/papers/7497580PubMed
7,236,488Enhanced cell killing in lewis lung carcinoma and a human pancreatic-carcinoma xenograft by the combination of cytotoxic drugs and misonidazole.Br J Cancer1981https://conductscience.org/library/papers/7236488PubMed
7,083,459Etoposide as a single agent in relapsed advanced lymphomas. A phase II study.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7083459PubMed
7,083,454Pharmacokinetics of VP16-213 given by different administration methods.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7083454PubMed
7,083,452Interaction of VP16-213 with the DNA repair antagonist chloroquine.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7083452PubMed
7,044,596Current development of podophyllotoxins.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7044596PubMed
7,044,594VP16-213 (etoposide). A critical review of its activity.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7044594PubMed
7,044,592The clinical pharmacology of VM26 and VP16-213. A brief overview.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7044592PubMed
7,044,591VP16-213 and podophyllotoxin. A study on the relationship between chemical structure and biological activity.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7044591PubMed
7,031,350[Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)].Klin Wochenschr1981https://conductscience.org/library/papers/7031350PubMed
6,861,265Flow-cytometric analysis of DNA distribution after VP16-213 treatment of Lewis lung carcinoma.Cancer Chemother Pharmacol1983https://conductscience.org/library/papers/6861265PubMed
6,690,078Phase II study of VP 16-213 (etoposide) in metastatic transitional cell urothelial cancer.Cancer Chemother Pharmacol1984https://conductscience.org/library/papers/6690078PubMed
6,481,426Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors.J Neurooncol1984https://conductscience.org/library/papers/6481426PubMed
6,282,480Epipodophyllotoxin (VP16-213) in small cell carcinoma of the Bronchus resistant to initial combination chemotherapy.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/6282480PubMed
3,555,940Pharmacokinetics of anticancer drugs in children.Clin Pharmacokinet1987https://conductscience.org/library/papers/3555940PubMed
3,410,665Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumors. A phase II study from the Pediatric Oncology Group.Invest New Drugs1988https://conductscience.org/library/papers/3410665PubMed
3,297,462The clinical pharmacology of etoposide and teniposide.Clin Pharmacokinet1987https://conductscience.org/library/papers/3297462PubMed

See all 26 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/389478

GET https://conductscience.org/api/papers/v1/389478/references?page=2